Histone deacetylase SIRT1 modulates pyroptosis in myocardial ischemia-reperfusion injury in rats
钟泽,罗秀英,相鹏,季红慧,吴新东,崇爱国,胡新央
DOI: https://doi.org/10.3760/cma.j.issn.2096-1588.2020.1000071
2020-01-01
Abstract:Objective:To investigate the effects and mechanism of the histone deacetylase silent information regulator 1 (SIRT1) on pyroptosis mediated by myocardial ischemia-reperfusion.Subjects:Ninty-five male Sprague Dawley (SD) rats, weighing 250-300 g, and eighty of them were randomly assigned to five groups: sham surgery group, model group, high SIRT1 expression (SIRT1 +) group, low SIRT1 expression (SIRT1 -) group, and adenosine monophosphate-activated protein kinase (AMPK) pathway inhibition group ( n=16 rats per group).The other fifteen rats were randomly assigned to three groups: control group, high SIRT1 expression (SIRT1 +) group, low SIRT1 expression (SIRT1 -) group ( n=5 rats per group). Interventions:Sham surgery group: thoracotomy was conducted to expose the heart, but myocardial ischemia-reperfusion was not performed. Model group: lentiviruses carrying an empty vector were injected intramyocardially, followed by the induction of myocardial ischemia-reperfusion 7 days later. SIRT1 + group: lentiviruses carrying the SIRT1 gene were injected intramyocardially, followed by the induction of myocardial ischemia-reperfusion 7 days later. SIRT1 -group: lentiviruses carrying small interfering RNAs (siRNAs) targeting SIRT1 were injected intramyocardially, followed by the induction of myocardial ischemia-reperfusion 7 days later. AMPK pathway inhibition group: lentiviruses carrying the SIRT1 gene were injected intramyocardially, followed by treatment with compound C, an AMPK pathway inhibitor, and the induction of myocardial ischemia-reperfusion 7 days later. Main Outcomes and Measurements:The rats were euthanized after model construction. Ischemic myocardial tissue was collected, and the activity of serum myocardial enzymes was measured via biochemical testing. Western blot analysis was employed to examine the expression levels of pyroptosis-associated proteins, including nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), caspase-1 P10, and interleukin-1β (IL-1β), as well as the activity of the AMPK signaling pathway. Pathological sections of the ischemic tissue were also prepared, and the TUNEL assay was performed to measure the apoptotic rate of cardiomyocytes. Statistical analysis was conducted using the SPSS 22.0 software. The expression levels are presented as the mean ± standard deviation (Mean±SD). Between-group comparisons were performed using the independent samples t-test. P values<0.05 were considered statistically significant. The GraphPad Prism 7 software was used to plot histograms. Results:Compared with the model group, the SIRT1+ group exhibited significantly reduced expression of creatine kinase-MB (CK-MB) [(961.64±11.62) vs.(1 400.32±16.16), P<0.05)] and lactate dehydrogenase (LDH)[(974.46±69.58) vs. (1 752.97±99.62), P<0.05), and a significantly reduced rate of apoptotic cardiomyocytes [(30.06±6.10) vs. (69.36±3.66), P<0.05]. The SIRT1 + group also showed significant decreases in the expression of pyroptosis-related proteins, including NLRP3 [(4.60±0.83) vs. (7.58±0.77), P<0.05), ASC[(2.90±0.19) vs. (5.28±0.59), P<0.05)], caspase-1 P10[(3.19±0.20) vs. (5.06±1.01), P<0.05], and IL-1β [(5.05±0.91) vs. (8.32±0.85), P<0.05], while the activity of the AMPK pathway was increased[(3.49±1.05) vs. (0.76±0.02), P<0.05]. Compared with the SIRT1 + group, the AMPK pathway inhibition group exhibited significantly elevated expression of CK-MB [(1 568.28±121.34) vs. (932.79±11.27), P<0.05] and LDH [(1 930.75±95.79) vs. (956.41±102.83), P<0.05)], the apoptotic rate of cardiomyocytes also increased significantly [(69.70±2.52) vs. (29.28±7.03), P<0.05]. Conclusion:The histone deacetylase SIRT1 reduces the expression of pyroptosis-associated proteins via the regulation of the AMPK signaling pathway, thereby alleviating myocardial ischemia-reperfusion injury.